ID   UT-SCC-110A
AC   CVCL_A7EB
SY   University of Turku-Squamous Cell Carcinoma-110B
DR   cancercelllines; CVCL_A7EB
DR   GEO; GSM2883394
DR   GEO; GSM2888857
DR   Wikidata; Q107117358
RX   DOI=10.1158/1538-7445.AM2020-507;
RX   PubMed=29970484;
RX   PubMed=30135316;
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Homozygous (PubMed=29970484).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Variations; Array-based CGH.
CC   Derived from site: In situ; Nose, nasal cavity, maxillary sinus; UBERON=UBERON_0001764.
ST   Source(s): PubMed=30135316
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 8
ST   D16S539: 11,12
ST   D18S51: 13,16,17
ST   D19S433: 14,16
ST   D21S11: 31,31.2
ST   D2S1338: 20
ST   D3S1358: 14,17
ST   D5S818: 11
ST   D7S820: 9,12
ST   D8S1179: 11,14
ST   FGA: 20
ST   TH01: 8
ST   TPOX: 8,10
ST   vWA: 16,17
DI   NCIt; C6064; Maxillary sinus squamous cell carcinoma
DI   ORDO; Orphanet_500464; Squamous cell carcinoma of the nasal cavity and paranasal sinuses
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_A091 ! UT-SCC-110B
SX   Male
AG   37Y
CA   Cancer cell line
DT   Created: 20-05-21; Last updated: 10-04-25; Version: 8
//
RX   DOI=10.1158/1538-7445.AM2020-507;
RA   Kondratyev M.K., Pesic A., Dvorkin-Sheva A., Ketela T., Moffat J.,
RA   Koritzinsky M., Wouters B.G.;
RT   "Repurposing of FDA approved drugs for treatment of metastatic HNSCC.";
RL   Cancer Res. 80 Suppl. 16:507-507(2020).
//
RX   PubMed=29970484; DOI=10.1158/1535-7163.MCT-17-0733;
RA   Lepikhova T., Karhemo P.-R., Louhimo R., Yadav B., Murumagi A.,
RA   Kulesskiy E., Kivento M., Sihto H., Grenman R., Syrjanen S.M.,
RA   Kallioniemi O.-P., Aittokallio T., Wennerberg K., Joensuu H., Monni O.;
RT   "Drug-sensitivity screening and genomic characterization of 45
RT   HPV-negative head and neck carcinoma cell lines for novel biomarkers
RT   of drug efficacy.";
RL   Mol. Cancer Ther. 17:2060-2071(2018).
//
RX   PubMed=30135316; DOI=10.1172/jci.insight.122204; PMCID=PMC6141174;
RA   Jamieson S.M.F., Tsai P., Kondratyev M.K., Budhani P., Liu A.,
RA   Senzer N.N., Chiorean E.G., Jalal S.I., Nemunaitis J.J., Kee D.,
RA   Shome A., Wong W.W., Li D., Poonawala-Lohani N., Kakadia P.M.,
RA   Knowlton N.S., Lynch C.R.H., Hong C.R., Lee T.W., Grenman R.,
RA   Caporiccio L., McKee T.D., Zaidi M., Butt S., Macann A.M.J.,
RA   McIvor N.P., Chaplin J.M., Hicks K.O., Bohlander S.K., Wouters B.G.,
RA   Hart C.P., Print C.G., Wilson W.R., Curran M.A., Hunter F.W.;
RT   "Evofosfamide for the treatment of human papillomavirus-negative head
RT   and neck squamous cell carcinoma.";
RL   JCI Insight 3:e122204.1-e122204.19(2018).
//